参考文献
[1] Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004 Apr 1;428(6982):486doi: 10.1038/428486a. PubMed PMID: 15057820.
[2] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. E14 Implementation Working Group. ICH E14 guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Questions and answers (R3). 10 December 2015. Accessed December 2016. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Q_As_R3__Step4.pdf
[3] James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507–20.doi: 10.1001/jama.2013.284427. PubMed PMID: 24352797.
[4] Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR; American Society of Clinical Oncology. American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010 Nov 20;28(33):4996–5010.doi: 10.1200/JCO.2010.29.2201. PubMed PMID: 20975064.
[5] Roush GC, Sica DA. Diuretics for Hypertension: A Review and Update. Am J Hypertens. 2016 Oct;29(10):1130–7.doi: 10.1093/ajh/hpw030. PubMed PMID: 27048970.
[6] Senior JR. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf. 2014 Nov;37 Suppl 1:S9–17.doi: 10.1007/s40264-014-0182-7. PubMed PMID: 25352324.
[7] Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO; American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199–212.doi: 10.1200/JCO.2015.62.3488. PubMed PMID: 26169616.
[8] U.S. Food and Drug Administration. Review of Qualification Data for Biomarkers of Nephrotoxicity Submitted by the Predictive Safety Testing Consortium. January 16, 2009. Accessed October 2016. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/UCM382536.pdf
[9] U.S. Food and Drug Administration. Review of Qualification Data for Biomarkers of Nephrotoxicity Submitted by the ILSI-HESI Nephrotoxicity Working Group. September 13, 2010. Accessed October 2016. Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/UCM382527.pdf
[10] U.S. Food and Drug Administration. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. October 2005. Accessed December 2016. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073153.pdf
[11] Wasung ME, Chawla LS, Madero M. Biomarkers of renal function, which and when? Clin Chim Acta. 2015 Jan 1;438:350–7.doi: 10.1016/j.cca.2014.08.039. PubMed PMID: 25195004.
/3 
浙公网安备33010802005999号 
